Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Sanofi-Aventis S.A. ADR (SNY)

Sanofi-Aventis S.A. ADR (SNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 147,556,624
  • Shares Outstanding, K 2,532,726
  • Annual Sales, $ 50,266 M
  • Annual Income, $ 5,844 M
  • 60-Month Beta 0.60
  • Price/Sales 3.12
  • Price/Cash Flow 8.90
  • Price/Book 1.83
Trade SNY with:

Options Overview Details

View History
  • Implied Volatility 21.63% ( -0.86%)
  • Historical Volatility 15.55%
  • IV Percentile 27%
  • IV Rank 20.23%
  • IV High 39.81% on 04/24/24
  • IV Low 17.02% on 03/11/24
  • Put/Call Vol Ratio 0.16
  • Today's Volume 3,707
  • Volume Avg (30-Day) 1,996
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 59,124
  • Open Int (30-Day) 54,363

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 1.38
  • Number of Estimates 5
  • High Estimate 1.45
  • Low Estimate 1.30
  • Prior Year 1.39
  • Growth Rate Est. (year over year) -0.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
54.89 +4.99%
on 08/21/24
58.97 -2.27%
on 09/04/24
+2.85 (+5.20%)
since 08/20/24
3-Month
46.51 +23.91%
on 06/21/24
58.97 -2.27%
on 09/04/24
+10.78 (+23.01%)
since 06/20/24
52-Week
42.63 +35.19%
on 10/27/23
58.97 -2.27%
on 09/04/24
+2.43 (+4.40%)
since 09/20/23

Most Recent Stories

More News
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies

/CNW/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84% increase...

ONCY : 0.9239 (-2.75%)
ACLX : 86.61 (+1.38%)
ONC.TO : 1.26 (-2.33%)
GTHX : 7.15 (unch)
HALO : 59.24 (-0.44%)
SNY : 57.63 (-1.08%)
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?

Sanofi’s SNY stock has gained 22.7% in the past three months compared with an increase of 2.9% for the industry. The stock has also outperformed the sector and the S&P 500 index as seen in the chart...

SNY : 57.63 (-1.08%)
AZN : 78.38 (-0.66%)
NVO : 127.51 (-5.46%)
LLY : 921.49 (+0.70%)
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease

AstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab) for a new indication. The regulatory body has now approved Fasenra for treating adult patients with...

REGN : 1,145.03 (-0.45%)
SNY : 57.63 (-1.08%)
AZN : 78.38 (-0.66%)
GSK : 40.80 (-1.97%)
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label

Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has approved blockbuster drug Dupixent (dupilumab) for the indication of chronic rhinosinusitis with nasal polyps (CRSwNP) for a broader population.The...

REGN : 1,145.03 (-0.45%)
SNY : 57.63 (-1.08%)
RHHBY : 39.4500 (-0.03%)
TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?

Teva Pharmaceutical Industries Limited’s TEVA stock has risen 72.5% so far this year compared with an increase of 17.9% for the industry. The stock has also outperformed the sector and the S&P 500, as...

SNY : 57.63 (-1.08%)
JNJ : 164.16 (-0.40%)
TEVA : 17.51 (-1.41%)
ABBV : 193.47 (-0.08%)
MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts

At its annual R&D Day, Moderna MRNA announcedseveral updates about the advancements in its pipeline and its business outlook for the next four years.MRNA to Cut R&D Costs, Stops Five Pipeline ProgramsManagement...

SNY : 57.63 (-1.08%)
GSK : 40.80 (-1.97%)
MRK : 117.17 (-0.05%)
MRNA : 65.69 (-3.43%)
Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More

This week, the FDA approved J&J’s JNJ Tremfya for treating an inflammatory bowel disease condition (“IBD”), ulcerative colitis. Novo Nordisk’s NVO oral obesity pill, amycretin, showed faster weight...

REGN : 1,145.03 (-0.45%)
SNY : 57.63 (-1.08%)
JNJ : 164.16 (-0.40%)
NVO : 127.51 (-5.46%)
Should You Buy Novavax Stock After This Regulatory Win?

The biotech continues to earn important wins, but is it enough?

MRNA : 65.69 (-3.43%)
BNTX : 112.28 (-0.20%)
JNJ : 164.16 (-0.40%)
PFE : 29.42 (-0.81%)
NVAX : 12.91 (+3.12%)
SNY : 57.63 (-1.08%)
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals

Sanofi SNY and Regeneron REGN announced encouraging data from the confirmatory phase III LIBERTY-CUPID C study evaluating their blockbuster drug Dupixent (dupilumab) in chronicspontaneous urticaria (CSU)...

REGN : 1,145.03 (-0.45%)
SNY : 57.63 (-1.08%)
NVS : 115.94 (-0.03%)
RHHBY : 39.4500 (-0.03%)
Prediction: These 2 Companies Will Split Their Stocks by 2027

Eli Lilly and Regeneron Pharmaceuticals are good stock-split candidates thanks to years of successes.

LLY : 921.49 (+0.70%)
REGN : 1,145.03 (-0.45%)
SNY : 57.63 (-1.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme,...

See More

Key Turning Points

3rd Resistance Point 58.39
2nd Resistance Point 58.18
1st Resistance Point 57.90
Last Price 57.63
1st Support Level 57.41
2nd Support Level 57.20
3rd Support Level 56.92

See More

52-Week High 58.97
Last Price 57.63
Fibonacci 61.8% 52.73
Fibonacci 50% 50.80
Fibonacci 38.2% 48.87
52-Week Low 42.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar